$-0.09
(Market cap
$26 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
9.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.2
-
Debt to Equity
0
-
Book Value
$-0.3
-
EPS
$-1.6
-
Face value
--
-
Shares outstanding
12,784,146
6 Years Aggregate
CFO
$-46.76 Mln
EBITDA
$-54.77 Mln
Net Profit
$-52.41 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Lantern Pharma (LTRN)
| -31.7 | -25.8 | -37.5 | -48.9 | -24.3 | -31.8 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Lantern Pharma (LTRN)
| -5.0 | -25.3 | -29.1 | -24.3 | -58.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Lantern Pharma (LTRN)
|
2.1 | 26.5 | 0.0 | -18.7 | -- | -- | -- | 9.7 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 144.3 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Lantern Pharma (LTRN)
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma;... LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas. Read more
-
President, CEO & Director
Mr. Panna Sharma PH.D.
-
President, CEO & Director
Mr. Panna Sharma
-
Headquarters
Dallas, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Lantern Pharma (LTRN)
What is the current share price of Lantern Pharma Inc (LTRN) Today?
The share price of Lantern Pharma Inc (LTRN) is $2.07 (NASDAQ) as of 28-Aug-2026 16:05 EDT. Lantern Pharma Inc (LTRN) has given a return of -24.34% in the last 3 years.
What is the current PB & PE ratio of Lantern Pharma Inc (LTRN)?
Since, TTM earnings of Lantern Pharma Inc (LTRN) is negative, P/E ratio is not available.
The P/B ratio of Lantern Pharma Inc (LTRN) is 9.74 times as on 28-Aug-2026, a 82 premium to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.93 |
5.05 |
2024 |
-1.66 |
1.62 |
2023 |
-2.90 |
1.13 |
2022 |
0.00 |
1.17 |
2021 |
-7.22 |
1.25 |
What is the 52 Week High and Low of Lantern Pharma Inc (LTRN)?
The 52-week high and low of Lantern Pharma Inc (LTRN) are Rs 4.70 and Rs 1.11 as of 30-Aug-2026.
What is the market cap of Lantern Pharma Inc (LTRN)?
Lantern Pharma Inc (LTRN) has a market capitalisation of $ 26 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Lantern Pharma Inc (LTRN)?
Before investing in Lantern Pharma Inc (LTRN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.